Clinical Trial Update: REGN5381 in Adult Participants With Uncontrolled Hypertension [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating REGN5381 in adults with uncontrolled hypertension has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• REGN5381

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Uncontrolled Hypertension | Phase 2 | Status: TERMINATED